Market Overview

Repligen Enters Global Licensing Agreement with Pfizer for Spinal Muscular Atrophy Program

Related RGEN
Mid-Morning Market Update: Markets Gain; Johnson & Johnson Profit Beats Street View
UPDATE: Repligen Launches OPUS(R) Ready-to-Use Chromatography Columns With Largest Capacity Available on the Market

Repligen Corporation (NASDAQ: RGEN) announced today that it has entered
into an exclusive worldwide licensing agreement with Pfizer (NYSE: PFE) to
advance Repligen's spinal muscular atrophy (SMA) program, originally
in-licensed from Families of SMA (FSMA). The SMA program includes
RG3039, a small molecule drug candidate in clinical development for SMA,
as well as backup compounds and enabling technologies. Under the terms
of the agreement, Repligen is entitled to receive up to $70 million from
Pfizer, commencing with an upfront payment of $5 million and total
potential future milestone payments of up to $65 million as well as
royalties on any future sales of SMA compounds developed under the
agreement. SMA is an orphan neurodegenerative genetic disease that
presents early in life.

See full press release

Posted-In: News Guidance Contracts Global

 

Most Popular

Related Articles (RGEN + PFE)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free